Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.

[1]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[2]  H. White,et al.  Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. , 2011, JACC. Cardiovascular interventions.

[3]  K. Alexander,et al.  Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. , 2011, American heart journal.

[4]  F. Van de Werf,et al.  Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.

[5]  S. Pocock,et al.  Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. , 2010, Journal of the American College of Cardiology.

[6]  M. Zubaid,et al.  Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE) , 2009, European journal of heart failure.

[7]  B. Gersh.  Thrombus Aspiration during Primary Percutaneous Coronary Intervention , 2009 .

[8]  J. Ornato,et al.  Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. , 2008, American heart journal.

[9]  Michael Weis,et al.  Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.

[10]  Á. Avezum,et al.  Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure , 2008, Circulation.

[11]  A. Parkhomenko,et al.  History of Hypertension and Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure , 2008, Hypertension.

[12]  M. Sabatine,et al.  Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. , 2008, JAMA.

[13]  J. O’Keefe,et al.  Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS , 2008, Diabetes, obesity & metabolism.

[14]  J. Avorn,et al.  Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. , 2008, Journal of the American College of Cardiology.

[15]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[16]  David O. Williams,et al.  Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). , 2007, The American journal of cardiology.

[17]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[18]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[19]  G. Filippatos,et al.  The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. , 2006, European heart journal.

[20]  J. McMurray,et al.  Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. , 2006, The American journal of cardiology.

[21]  J. Cohn,et al.  Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. , 2006, The American journal of cardiology.

[22]  A. Parkhomenko,et al.  Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30% , 2006, European journal of heart failure.

[23]  C. Terkelsen,et al.  Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. , 2005, European heart journal.

[24]  M. Pfeffer,et al.  An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. , 2004, European heart journal.

[25]  M. Pfeffer,et al.  Acute heart failure complicating acute coronary syndromes: a deadly intersection. , 2004, Circulation.

[26]  A. Cohen-Solal,et al.  Determinants and Prognostic Impact of Heart Failure Complicating Acute Coronary Syndromes: Observations From the Global Registry of Acute Coronary Events (GRACE) , 2004, Circulation.

[27]  M. Pfeffer,et al.  VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context , 2003, European journal of heart failure.

[28]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[29]  L. Parsons,et al.  Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). , 2002, Journal of the American College of Cardiology.

[30]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[31]  M L Simoons,et al.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.

[32]  Christoph Haenel,et al.  The History of π , 2001 .

[33]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations , 2000, Circulation.

[34]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[35]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations , 1999, The Lancet.

[36]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[37]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. , 1999, Lancet.

[38]  M. Davies.  The composition of coronary-artery plaques. , 1997, The New England journal of medicine.

[39]  M J Davies,et al.  Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. , 1995, European heart journal.

[40]  M. Davies,et al.  Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. , 1993, British heart journal.

[41]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.